Aims The established risk factors for severe sulfonylureainduced hypoglycemia (SH) include low hemoglobin (Hb) 
Introduction
Recent results from large interventional studies [1] [2] [3] for the prevention of vascular complications and data from observational studies [4] revealed that tight glycemic control in patients with type 2 diabetes mellitus (T2DM) is of limited value. In particular, severe hypoglycemia may even increase cardiovascular and all-cause mortality rates. These inferences also apply for sulfonylurea (SU)-treated diabetic patients. Severe SU-induced hypoglycemia (SH) is a life-threatening and pathophysiologically complex, multifactorial event. The established risk factors for SH include low hemoglobin (Hb)A 1c , advanced age, long diabetes duration, extensive comorbidity with higher degrees of renal insufficiency, polypharmacy, and the use of longacting versus short-acting preparations [5, 6] .
In characterizing individual sensitivity to SUs, pharmacogenetic factors could be of additional critical importance in SH risk factors. SUs such as glibenclamide, glimepiride, gliclazide, or gliquidone are metabolized hepatically by the genetically polymorphic cytochrome P450 (CYP) enzyme CYP2C9 [7, 8] . There have been few studies examining the role of CYP2C9 genotypes for interindividual variability in drug response [9, 10] and mild hypoglycemia [11] . However, previous studies did not capture the significance of CYP2C9 variants in patients with experienced SH. Only in a pilot study with a small sample size did we identify the CYP2C9 genotypes *2/*3 and *3/*3 that are predictive of low enzyme activity as further risk factors for SH in Caucasian individuals [12] . In the study presented here, we compared the distribution of different CYP2C9 allelic variants in a large cohort of patients (by international standards) with T2DM who experienced SH, versus a matched control group without SH. Furthermore, the frequency of CYP2C9 genotypes in patients with SH was compared with a second, previously reported, control sample of DNA from 337 Caucasian diabetic patients receiving antidiabetic drugs per os and without a history of severe hypoglycemia, and with a further sample of 1,988 healthy Caucasian volunteers.
Patients and methods
In this prospective population-based case-control study, 102 consecutive patients with T2DM and SH were genotyped for CYP2C9 allelic variants and compared with a matched control group of 101 SU-treated patients without a history of SH. The hypoglycemic and control patient groups were recruited at the medical department of the Clinic LippeDetmold, a large tertiary-care hospital in East Westphalia, Germany, between 1 January 2000 and 31 December 2009. As the only hospital in the area, the Clinic Lippe-Detmold is responsible for inpatient and outpatient management of all emergencies in a region with 200,000 inhabitants. Our study provided a sensitive detection of hypoglycemia. As published previously, blood glucose testing was systematically performed in every emergency patient irrespective of the presenting condition, either at the scene of the emergency or immediately upon arrival at the emergency department. The entire emergency team underwent a structured training program concerning the diagnosis and therapy of diabetic emergencies [6, 13] .
All 203 Caucasian diabetic patients investigated had been treated with the SUs glimepiride, glibenclamide (glyburide), or gliquidone and were monitored on an inpatient basis. Severe hypoglycemia was restrictively defined as a symptomatic event requiring treatment with intravenously administered glucose and was confirmed by a blood glucose measurement of <50 mg/dl (<2.8 mmol/l). Creatinine clearance was calculated by the formula of Cockroft and Gault [14] . Renal impairment was defined as a creatinine clearance of <60 ml / min.
After receiving informed consent , we collected 10 ml ethylenediaminetetraacetate (EDTA) blood samples from all 203 patients and CYP2C9 genotyping was performed with the methods described earlier [8] Clinicians and patients were blinded to genotype. Frequency of genotypes in patients with SH was compared with patients in the matched control group. Furthermore, we performed a comparison between patients with SH and a second control sample of DNA from 337 Caucasian diabetic patients receiving antidiabetic drugs per os without a history of severe hypoglycemia, and to a further large sample of 1,988 healthy Caucasian volunteers who had given their informed consent for genotyping [12] . The protocol was approved by the Ethics Committee of the University of Münster School of Medicine and (for further comparison groups) by the Ethics Committee of the Charité University hospital, University Medicine Berlin.
Statistics
Standard descriptive and comparative statistics [χ 2 test, analysis of variance (ANOVA)] was used to characterize and compare clinical parameters in different groups (cases, controls). Logistic regression analyses were used to calculate the effects of investigated factors on severe hypoglycemic events, which were reported as odds ratio (OR) with 95% confidence intervals (CI). Data were analyzed using the SPSS software package (version 18.0.2; SPSS, Inc., Chicago, IL, USA).
Results
From 2000 to 2009, 1,419 cases of severe hypoglycemia were registered among the 103,256 patients who attended the emergency department of the Lippe-Detmold Clinic. Thirty-nine percent (552/1,419) of hypoglycemic events occurred in patients with type 1 and 57% (809/1,419) in patients with type 2 diabetes. In 4% (58/1,419) patients with secondary diabetes and nondiabetics were affected. Ten percent (141/1,419) of all cases with severe hypoglycemia had been treated with SUs. In two cases, ingestion of SUs was accidental, as two women with dementia took the SU preparations from their husbands. Genotyping could be performed in 102 individuals with SH, as another 37 patients were not able to consent due to their demented state or explicitly gave no consent.
All 102 patients with SH demonstrated neuroglycopenic disturbances; their plasma glucose levels were 31.8± 10.4 mg/dl (1.76 mmol/l) prior to treatment with i.v. glucose. The distribution and mean daily dose of SU agents were comparable between hypoglycemic patients and controls. Table 1 demonstrates the basic characteristics of all hypoglycemic individuals versus the control group, indicating a comparable geriatric and multimorbid state in both groups. The control group without SH had even a higher degree of renal impairment and received more additional comedication, which were main substrates of CYP2C9, than did patients with SH, in particular torsemide, clopidogrel, phenprocoumon, diclofenac, or fluvastatine.
Logistic regression analysis revealed a low HbA 1c , presence of coronary heart disease (CHD), CYP2C9 genotypes (*1/*2 and *2/*3), and comedication with other CYP2C9 main substrates as significant risk factors for SH ( Table 2 ). The effects of these predictors appeared to be independent of each other, as they remained statistically significant in logistic regression analysis even upon including all risk factors in the model (HbA 1c , presence of CHD, comedication with other CYP2C9 main substrates; all p<05). The type of accommodation of the patients, their previous diabetes education, different comorbidities (dementia, heart failure), or comedication [insulin, metformin, angiotensin-converting enzyme inhibitors (ACEIs), etc.] did not influence the risk of SH.
There was no overrepresentation of the CYP2C9 slowmetabolizer genotypes *2/*3 and *3/*3 in our group with SH compared with the control group. Accordingly, we found no significant differences in the distribution of CYP2C9 allelic variants compared with two other previously reported control samples [12] consisting of 337 Caucasian diabetic patients receiving oral antidiabetic drugs and without a history of SH, and to a large cohort of 1,988 healthy Caucasian volunteers (Table 3) .
By expressing drug dosing as a dose factor with 3.5 mg glyburide, 1 mg glimepiride, and 30 mg gliquidone as normal dose with dose factor 1, we calculated mean doses in the CYP2C9-metabolizer groups extensive (alleles CYP2C9*1/*1, *1/*2), intermediate (CYP2C9*1/*3), and slow (CYP2C9*2/*2, *2/*3, and *3/*3). The mean SU dose was 2.3, 1.8, and 1.7 in the extensive-, intermediate-, and slow-metabolizer groups in the control group and 2.5, 2.9, and 2.8 in the hypoglycemic patient group. A significant lowering of the doses thus could be observed in the control group (p=0.027), whereas in the hypoglycemic patient group, no such empirical dose adjustment to genotype was seen.
Discussion
The current ten-year population based study suggest that apart from the established clinical risk conditions, CYP2C9 allelic variants do not strongly contribute to the individual susceptibility for severe hypoglycemia associated with the use of glimepiride and glibenclamide. The frequency of the CYP2C9 slow metabolizer genotypes *2/*2, *2/*3, and *3/*3 in our cohort of 102 Caucasian individuals with SH Bolded data indicate that these results have statistical significance did not differ from that observed in the control group. SUs are mainly metabolized by the genetically polymorphic cytochrome enzyme CYP2C9. The rare CYP2C9 genotypes *2/*2, *2/*3, and *3/*3 are predictive for low enzyme activity. In vitro and in vivo studies showed a modest reduction of enzyme activity in healthy volunteers with the CYP2C9*2 polymorphism and a strong reduction in those with the CYP2C9*3 polymorphism. Compared with the CYP2C9*1/*1 genotype, the tolbutamide clearance in individuals with the CYP2C9*2/*2 genotype was reduced by 25% and in those with the CYP2C9*3/*3 genotype by 84% [7] . Pharmacokinetic studies in healthy individuals revealed that glibenclamide and glimepiride clearance in CYP2C9*3/*3 carriers was only 20% of that in wild-type carriers [8] . Also nondiabetic carriers of the CYP2C9*2/*3 genotype had a significantly reduced clearance of glibenclamide and glimepiride [9] . Using these SUs, the drug exposure was increased 1.3-to 2.8-fold in volunteers with a CYP2C9*3 allele compared with those with the CYP2C9*1/*1 genotype [9, 15, 16] . In CYP2C9*3 allele carriers using tolbutamide, the prescribed dose was lower compared with that for patients with the wild-type CYP2C9 genotype. No differences in the prescribed dose were found in tolbutamide users with the CYP2C9*1/*2 or CYP2C9*2/*2 genotype compared with wild-type patients or in patients using glibenclamide, gliclazide, or glimepiride [10] . Recent ***Cases with SH vs previously reported healthy controls [12] a P values were calculated using chi-square tests to compare overall distribution of CYP2C9 allelic variants between cases and controls b P values were calculated by using Fisher's exact tests to compare frequencies of CYP2C9 *2/*3 and CYP2C9 *3/*3 allelic variants between cases and controls data from the Genetics of Diabetes Audit and Research Tayside (GoDARTS) study of 1,073 SU-treated patients (80% received gliclazide) indicated that patients with two copies of the CYP2C9*2 or CYP2C9*3 loss-of-function alleles were 3.4 times more likely to achieve a treatment HbA 1c level of <7% compared with wild-type carriers, resulting in a 0.5% greater reduction in HbA 1c [17] . Indeed, we observed an empirically lower dosing in patients with the genotypes *2/*2, *2/*3, or *3/*3 within the control group, indicating that clinicians and patients became aware of the lower oral clearance of SU drugs due to the CYP2C9 genotypes and took lower doses. Interestingly, we did not observe this genotype based dosing within the hypoglycemic patient group. A higher drug exposure thus might have contributed to the risk of hypoglycemia in patients with the CYP2C9 slow-metabolizer genotypes. Our study examined CYP2C9 allelic variants in a typical cohort with experienced SH. As there is no consensus, definition of hypoglycemia in diabetes is a critical point. Our definition of severe hypoglycemia as an event with neuroglycopenic symptoms requiring treatment with i.v. glucose and confirmation by a blood glucose measurement of <50 mg/dl (<2.8 mmol/l) was chosen restrictively and was indisputable in large degree with the American Diabetes Association (ADA) definition [18] and comparable studies [19] . In a recent study by Ragia et al. [11] , the diagnosis of hypoglycemia was assessed retrospectively and was not based on accepted standards, as it included self-reported unspecific symptoms with incomplete confirmation of a blood glucose concentration <65 mg/dl (<3.6 mmol/l). The authors demonstrated that the CYP2C9*3 allele was a determinant for mild hypoglycemia in 92 patients treated with glimepiride or gliclazide. However, compared with our cohort, their patients were significantly younger (mean age 68 vs 77 years), less morbid, and with poor metabolic control (HbA 1c 7.6 vs 6.5%), thus predicting an a priori low risk for hypoglycemia.
Whereas our small-sized initial study [12] showed an overrepresentation of *2/*3 and *3/*3 genotypes (10%) in 20 patients with SH compared with the normal population (2.1%), our substantially larger study reported here could not replicate these findings in this dimension. However, a combined effect of genotype and dosing might have contributed to higher drug exposure in patients with low CYP2C9 activity genotypes, thereby increasing their risk for hypoglycemia. Consistently with previous studies [20, 21] , our results confirmed the established risk factors for SH: low HbA 1c , advanced age, long diabetes duration, extensive comorbidity with higher degrees of renal insufficiency, and polypharmacy, thus emphasizing the general representativity and validity of our cohort. Surprisingly, in the GoDARTS study, there was a lack of effect of the *3/*3 genotype on HbA 1c reduction [17] , indicating that the individual response to SUs, and also the risk for SH, are pathophysiologically complex and multifactorial. Besides the influence of CYP2C9 variants, polymorphisms of other genes might also be involved in the individual response to SUs and the risk of SH. Plausible candidate genes could be those involved in β-cell function control, such as KCNJ11 (potassium inwardly rectifying channel, subfamily J, member 11) or transcription-factor-7-like 2 (TCF7L2). In a subgroup of the 102 individuals with SH in the study reported here, we demonstrated that those carrying the K variant of the E23K polymorphism in KCNJ11 have reduced response to SU therapy, which results in increased HbA 1c and consequently lower risk for SH [22] . Continuing advances in genetic discovery will uncover further loci that are associated with T2DM, including variants that appear to modify responses to SUs. Additional medication metabolized through CYP2C9 might reduce SU metabolism of SUs and by increasing their hypoglycemic effects might ultimately result in SH. Twenty-four percent of individuals with SH versus 49% of our control group received additional medication, also consisting of the main substrates of CYP2C9. So it is unlikely that CYP2C9-dependent co-medication would be responsible for the lower HbA 1c as well as SH events in our cohort. It is also noteworthy that creatinine clearance was significantly lower in our control group. Based on this, the control group would actually have been expected to be at higher risk for SH. Thus, CYP2C9-dependent co-medication and higher degree of renal impairment do not explain the higher risk for SH, either.
In conclusion, our data suggest that under the conditions of everyday practice, individual susceptibility for SH associated with the use of glimepiride or glibenclamide is complex, with HBA 1c being the most important clinical risk factor. However, the observed interaction between dose and CYP2C9 genotype leading to potentially higher exposure in slow metabolizers at equal doses points to the benefit of individualized, and sometimes pharmacogenetic-based, dosing.
